Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 23

PMID 35317079

Authors

Fahai Chen

Jianmin Fang

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the tumor-related infiltrating lymphocytes (TILs) affecting the response of trastuzumab and identify potential biomarkers based on immune-related genes to improve prognosis and clinical outcomes of targeted therapies in breast cancer.

Methods: Estimation of stromal and immune cells in malignant tumors using expression data (ESTIMATE) was adopted to infer the fraction of stromal and immune cells through utilizing gene expression signatures in breast tumor samples. Cell-type identification by estimating relative subsets of RNA transcript (CIBERSORT) algorithm was applied to characterize cell composition of 22 lymphocytes from breast cancer tissues using their gene expression profiles. Immune-related genes were collected from the Immunology Database and Analysis (ImmPort). Univariate and multivariate Cox regression analyses were performed to identify the significant independent risk factors associated with poor overall survival (OS) and breast cancer-specific survival (BCSS) of breast cancer patients. Hub genes were identified based on the protein-protein interaction (PPI) network analysis.

Results: Based on the ESTIMATE algorithm, a significant reduction of stromal scores was observed in tumor tissues and pretreated tumor tissues compared with nontumor and posttreated tumor tissues, respectively, while immune scores failed to present notably statistical differences between both groups. However, from the results of the univariate Cox regression analysis, the immune score was identified to be remarkably associated with the poor OS for breast cancer patients. Subsequently, the infiltrating lymphocytes were evaluated in tumor tissues based on the CIBERSORT algorithm. Furthermore, significance analysis identified 1,244 differentially expressed genes (DEGs) from the GSE114082 dataset, and then 91 overlapping immune-related DEGs were screened between GSE114082 and ImmPort datasets. Subsequently, 10 top hub genes were identified and five (IGF1, ADIPOQ, PPARG, LEP, and NR3C1) significantly correlated with worse OS and BCSS on response to trastuzumab in breast cancer patients.

Conclusions: This study provided an insight into the immune score based on the tumor-related infiltrating lymphocytes in breast cancer tissues and demonstrates the benefits of immune infiltration on the treatment of trastuzumab. Meanwhile, the study established a novel five immune-related gene signature to predict the OS and BCSS of breast cancer treated by trastuzumab.

Citing Articles

Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.

Li L, Yang W, Jia D, Zheng S, Gao Y, Wang G Breast Cancer. 2023; 30(4):666-684.

PMID: 37178414 PMC: 10284980. DOI: 10.1007/s12282-023-01458-1.

SPOCK2 Promotes the Malignant Behavior of Ovarian Cancer via Regulation of the Wnt/-Catenin Signaling Pathway.

Zhao S, Liu H, Fan M Biomed Res Int. 2022; 2022:9223954.

PMID: 36193300 PMC: 9525767. DOI: 10.1155/2022/9223954.

References

Hollmen M, Roudnicky F, Karaman S, Detmar M . Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci Rep. 2015; 5:9188. PMC: 4361875. DOI: 10.1038/srep09188. View

Park Y, Lal S, Lee J, Choi Y, Wen J, Ram S . Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun. 2020; 11(1):6175. PMC: 7710739. DOI: 10.1038/s41467-020-19933-0. View

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

Samani A, Yakar S, LeRoith D, Brodt P . The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2006; 28(1):20-47. DOI: 10.1210/er.2006-0001. View

Burugu S, Asleh-Aburaya K, Nielsen T . Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2016; 24(1):3-15. DOI: 10.1007/s12282-016-0698-z. View

Emens L, Ascierto P, Darcy P, Demaria S, Eggermont A, Redmond W . Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017; 81:116-129. DOI: 10.1016/j.ejca.2017.01.035. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Clark J, Flanagan M, Telliez J . Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014; 57(12):5023-38. DOI: 10.1021/jm401490p. View

10.

Murphy N, Knuppel A, Papadimitriou N, Martin R, Tsilidis K, Smith-Byrne K . Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol. 2020; 31(5):641-649. PMC: 7221341. DOI: 10.1016/j.annonc.2020.01.066. View

11.

Qiu S, Waaijer S, Zwager M, de Vries E, van der Vegt B, Schroder C . Tumor-associated macrophages in breast cancer: Innocent bystander or important player?. Cancer Treat Rev. 2018; 70:178-189. DOI: 10.1016/j.ctrv.2018.08.010. View

12.

Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W . The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant. 2003; 4(1):51-7. DOI: 10.1046/j.1600-6143.2003.00281.x. View

13.

Meads M, Gatenby R, Dalton W . Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9(9):665-74. DOI: 10.1038/nrc2714. View

14.

Wu T, Dai Y . Tumor microenvironment and therapeutic response. Cancer Lett. 2016; 387:61-68. DOI: 10.1016/j.canlet.2016.01.043. View

15.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

16.

Owen K, Brockwell N, Parker B . JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers (Basel). 2019; 11(12). PMC: 6966445. DOI: 10.3390/cancers11122002. View

17.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

18.

Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

19.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

20.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F . Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7. DOI: 10.1200/JCO.2011.41.0902. View